Liquidia Corporation with ticker code (LQDA) have now 5 analysts covering the stock. The analyst consensus points to a rating of ‘Buy’. The range between the high target price and low target price is between 6 and 4 calculating the average target price we see 5.2. With the stocks previous close at 3.13 this would indicate that there is a potential upside of 66.1%. The 50 day moving average now sits at 3.32 while the 200 day moving average is 5.37. The market cap for the company is $130m. Find out more information at: http://www.liquidia.com
The potential market cap would be $216m based on the market concensus.
Liquidia Corporation, through its subsidiaries, operates as a late-stage clinical biopharmaceutical company. The company focuses on the development and commercialization of various products using its PRINT technology that enables precise production of drug particles designed to enhance the safety, efficacy, and performance of a range of therapies. Its product candidates include LIQ861 for the treatment of pulmonary arterial hypertension; and LIQ865 for the treatment of local post-operative pain. The company also provides strategy, investment, and commercialization services for rare disease pharmaceutical products, such as generic Remodulin, a parenteral formulation of treprostinil for pulmonary arterial hypertension. Liquidia Corporation was founded in 2004 and is based in Morrisville, North Carolina.
